Appendix B: Panel Roster and Financial Disclosures
Human Papillomavirus
| Member | Institution | Financial Disclosure | |
|---|---|---|---|
| Company | Relationship | ||
| Susan Cu-Uvin* | The Warren Alpert Medical School of Brown University | AIDS Malignancy Consortium | Data Safety Monitoring Board Chair/Member |
| International Antiviral Society–USA | Honoraria | ||
| Speaker | |||
| UpToDate | Honoraria | ||
| Author | |||
| Mark Einstein | Rutgers New Jersey Medical School | AstraZeneca Iovance Biotherapeutics Johnson & Johnson Pfizer VBL Therapeutics | Research Support (paid to institution) |
BD Douglas Pharmaceuticals Inovio Pharmaceuticals Merck PapiVax PDS Biotechnology | Consulting Fee (paid to institution) | ||
| Lauri Markowitz | Centers for Disease Control and Prevention | None | N/A |
| L. Stewart Massad | Washington University School of Medicine in St. Louis | None | N/A |
| Anna-Barbara Moscicki | David Geffen School of Medicine at the University of California, Los Angeles | Merck | Advisory Board |
| Joel Palefsky | University of California, San Francisco School of Medicine | Merck | Research Support (paid to institution) |
| Elizabeth Stier | Boston University Medical Center | None | N/A |
| John Weiser | Centers for Disease Control and Prevention | None | N/A |
| Timothy Wilkin | NewYork–Presbyterian/Weill Cornell Medicine | Merck | Scientific Advisory Board |
| Merck ViiV Healthcare | Research Support (paid to institution) | ||
| * Section Group Lead Note: Members are required to update disclosures annually and to notify guideline staff of any relevant changes in status during the interim. | |||
Download Guidelines
- Section Only PDF (22.06 KB)
- Full Guideline PDF (6.02 MB)
- Tables Only PDF (1.18 MB)